An alternative approach to reducing tauopathy involves the use of anti-tau antibodies (e.g., semorinemab, gosuranemab, zagotenemab, tilavonemab) and anti-tau vaccines (e.g., AADvac1, ACI-35), which are currently in clinical trials and appear to show promising efficacy in the treatment of AD [3,8]. The gene discussed is MAPT; the disease is Alzheimer disease.